A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial protocol-Reference-Cited by-同舟云学术

A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial protocol

Published:2021-05-06 Issue:S1 Volume:128 Page:9-17
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Moe Andrew¹²³^ORCID,Liow Elizabeth³,Redfern Andrew¹²⁴,Swarbrick Nicole⁵⁶,Ferguson Tom²,Davis Ian D.³⁷⁸,Hayne Dickon¹²³

Affiliation:

1. University of Western Australia (UWA) Medical School University of Western Australia PerthWAAustralia

2. Urology and Medical Oncology Departments South Metropolitan Health Service Perth WAAustralia

3. Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Camperdown NSWAustralia

4. Cancer Division Harry Perkins Institute of Medical Research PerthWAAustralia

5. Department of Anatomical Pathology PathWest Laboratory Medicine WA PerthWAAustralia

6. Division of Pathology and Laboratory Medicine UWA Medical School University of Western Australia Perth WAAustralia

7. Eastern Health Clinical School Monash University MelbourneVic.Australia

8. Department of Oncology Eastern Health Melbourne Vic. Australia

Funder

AstraZeneca

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15365

Reference40 articles.

1. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

2. Guideline of guidelines: non-muscle-invasive bladder cancer

3. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

4. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer;annals of urologic oncology;2024-08-29

2. U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes;ESMO Open;2024-07

3. Amplifying the Patient's Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers;American Society of Clinical Oncology Educational Book;2024-06

4. Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC);Research and Reports in Urology;2024-04

5. The SUB‐urothelial DUrvalumab InjEction‐1 (SUBDUE‐1) trial: first‐in‐human trial in patients with bladder cancer;BJU International;2024-03-12